Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors

BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients...
April 06, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

BLACKSBURG, Va., April 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients...
March 04, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers

NX-13 was well tolerated with no reported serious adverse events All primary and secondary endpoints in the Phase 1 study of NX-13 were met Landos expects to initiate a Phase 1b trial of NX-13 in...
February 23, 2021 16:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients...
February 03, 2021 20:13 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces Pricing of Initial Public Offering

BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune...
January 04, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients with Ulcerative Colitis

-Once a day oral dosing with BT-11 induced placebo-adjusted clinical remission rates of up to 11.5% at week 12--A small subset of biologic-experienced patients also showed positive trends in clinical...
July 14, 2020 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel Disease

BLACKSBURG, Va., July 14, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune...
May 12, 2020 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma to Present at Two Upcoming Investor Conferences

BLACKSBURG, Va., May 12, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune...
March 24, 2020 16:05 ET | Source: Landos Biopharma, Inc.

Landos Biopharma to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

BLACKSBURG, Va., March 24, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, today announced that Josep Bassaganya-Riera, Ph.D., Chairman, President and Chief Executive Officer, plans to present an...
February 26, 2020 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference

BLACKSBURG, Va., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune...